Hemophilia Treatment Market
Market Insights on Hemophilia Treatment covering sales outlook, demand forecast & up-to-date key trends
Hemophilia Treatment Market by Disease, Patient, Treatment, Therapy, Drug Class, Route of Administration & Region - Forecast 2022 - 2032
Hemophilia Treatment Market Outlook (2022-2032)
[312 Pages Report] The global hemophilia treatment market size was estimated to be worth around US$ 11.1 Bn in 2021. However, with rapidly increasing hemophilia patient pool worldwide and advancements in hemophilia treatment approaches, the overall demand for hemophilia treatment is projected to rise at 4.8% CAGR during the forecast period, surpassing a valuation of US$ 17.92 Bn by the end of 2032.
|
Attribute |
Details |
|
Hemophilia Treatment Market Size (2021) |
US$ 11.1 Bn |
|
Hemophilia Treatment Market Projected Size (2032) |
US$ 17.92 Bn |
|
Hemophilia Treatment Market size (2026) |
US$ 14.2 Bn |
|
Hemophilia Treatment Market Value CAGR (2022-2032) |
4.8% |
|
Top Players |
Biotest AG, Pfizer, CSL Behring, Biogen, Kedrion, Ferring B.V, Genentech, Novo Nordisk, and Octapharma |
Hemophilia is an inherited genetic disorder that impairs the body's ability to make blood clots. It occurs when there is any mutation or change in one of the genes that provide instructions for making the clotting factor proteins needed to form a blood clot. As a result, people with this condition (hemophilia) suffer from excessive bleeding after any injury or damage.
As hemophilia is a genetic disorder, there is currently no permanent cure for this medical condition. However, people use various hemophilia treatment therapies to replace the missing factor proteins needed for initiating blood clotting. Adoption of hemophilia treatments like replacement therapy and gene therapy significantly improves the life quality of patients.
Thus, rising incidence of hemophilia and increasing need for improving the quality of patient's life will continue to push the demand for hemophilia treatment during the forecast period.
Consequently, expansion of hemostats for wound close market and advancements in pharmaceutical drug delivery are likely to assist the hemophilia treatment market growth during the upcoming period.
Let us know your requirement to get
100% FREE customization
2057-2021 Global Hemophilia Treatment Market Outlook Compared To 2022-2032 Forecast
As per FMI, the global hemophilia treatment market is projected to expand at a moderate CAGR of 4.8% during the forecast period from 2022 to 2032. Growth in the market is attributed to the rising prevalence of hemophilia worldwide, advancements in hemophilia treatment therapies, rise in rate of diagnostic screening, and increasing government investments and initiatives to reduce the burden of hemophilia.
Hemophilia treatment consists of a wide range of therapies or medications used to improve blood clotting. These therapies work by mimicking the activities of missing or inadequate factor proteins needed for blood clotting.
Over the years, demand for hemophilia treatments such as replacement therapy has risen at a substantial pace on account of their highly effective nature and the trend is expected to continue during the forecast period. During replacement therapy, concentrates of clotting factor VII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly injected into a vein, where they replace the missing proteins.
Rapidly increasing number of patients suffering from hemophilia is a major factor driving the growth in the hemophilia treatment market. According to the World Federation of Hemophilia (WFH), there were around 393000 people with blood disorders identified and reported globally in 2020. Out of this, 241535 suffered from hemophilia A or B and type unknown. This rise in cases will eventually boost the growth of hemophilia treatment market during the forecast period.
Similarly, advancements in rare disease gene therapy market coupled with increasing research and development activities will favor the growth of hemophilia treatment market.
The latest hemophilia treatment drug industry analysis indicates that reduction in hemophilia treatment cost and escalating government initiatives to increase diagnostic screening of hemophilia as well as to educate people about hemophilia and its treatments will help hemophilia drug companies to increase sales.
Leading hemophilia treatment companies are continuously innovating to expand their customer base and stay relevant in the market. For instance, in 2020 TAKEDA Pharmaceutical Company enabled hemophilia A personalized care by launching MYPKFIT SOFTWARE for ADYNOVATE, the first and only FDA-approved pharmacokinetic dosing software and patient app available for ADYNOVATE patients of 12 and older.
What Factors are Limiting the Growth of the Hemophilia Treatment Market?
Some of the major factors restraining the growth of hemophilia treatment market are the high hemophilia treatment cost, low diagnostic screening rates across low economies, and lack of awareness among people regarding hemophilia and its treatments in some regions
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystCountry-wise Insights
What is the Demand Outlook for the U.S. Hemophilia Treatment Market?
“Rising Hemophilia Patient Pool Driving Market Growth in the U.S.”
As per FMI, the U.S. accounts for the largest share of the global hemophilia treatment market in 2022 and is expected to grow at a considerable pace during the forecast period. Growth in the market is driven by increased number of hemophilic patients, availability of new-gen technology like hemophilia gene therapy, rising diagnostic screening, presence of leading market players, surge in new drug launches and approvals, and increasing investments in research and development.
According to the National Hemophilia Foundation, there are around 30000 to 33000 people living with hemophilia in the United States and this number is likely to continue rising during the forthcoming period, thereby creating growth prospects within the U.S. hemophilia treatment market.
Similarly, rising demand for recombinant and plasma derived products, growing popularity of gene therapy, and increasing hemophilia research will expand the hemophilia treatment market size in the U.S.
What Makes China an Attractive Market for Hemophilia Treatments?
“Increase in Gene Therapy Research and Favorable Government Support Augmenting Market Growth in China”
With rapidly growing population, increasing prevalence of hemophilia, presence of lax government regulations, and favorable government initiatives, the hemophilia treatment market in China is poised to expand at a rapid pace during the forecast period.
Similarly, advancement in genetic research, new product launches and approvals, growing health awareness among people, and surge in diagnostic screening are expected to push the demand for the hemophilia treatment in China.
For instance, in August 2021 Belief Biomed's Gene Therapy for Hemophilia B (BBM-H901) received China’s National Medical Products Administration (NMPA) IND approval and the company successfully completed dosing of the first subject in the registrational gene therapy clinical trial for hemophilia B in 2022.
Country-wise Insights
Which Disease Segment holds the Maximum Growth Potential?
“Rising Prevalence of Hemophilia a Creating Maximum Growth Prospects”
Based on disease, the global market has been segmented into hemophilia A, and hemophilia B. Among these, hemophilia A segment dominated the global hemophilia treatment market in 2021 and is expected to grow at a relatively higher CAGR during the forecast period. Growth of the segment is attributed to the rising prevalence of hemophilia A worldwide.
Hemophilia A, also called classic hemophilia, is the most common type of hemophilia caused by a deficiency of factor VIII (one of the proteins that helps blood to form clots). Rise in diagnostic rate of hemophilia A along with growing awareness among people about its (hemophilia A) treatments will continue to favor the segment growth during the forecast period.
Which Patient Segment Leads the Hemophilia Treatment Market Growth?
“Adults Segment to Contribute Most to the Growth of Hemophilia Treatment market”
By patient, the global hemophilia treatment market is segmented into pediatric and adult. Among these, the adult segment is expected to hold the largest share of the hemophilia treatment market during the forecast period, owing to the increasing cases of hemophilia among the adult population and higher detection rates in adults.
Which is the Most Opted Treatment in the Hemophilia Treatment Market?
“Demand for prophylaxis To Remain High Throughout the Forecast Period”
In terms of treatment, the global hemophilia treatment market is segmented into prophylaxis and on-demand treatment. As per FMI’s latest hemophilia treatment market forecast, the prophylaxis segment is expected to dominate the global hemophilia treatment market during the assessment period.
Prophylaxis treatment has become the standard of care for better treatment in adult patients with hemophilia. People suffering from hemophilia are increasingly opting for prophylaxis treatment to prevent hemophilia/bleeding. As per CDC, prophylaxis decreases the risk of intracranial bleeding by 50% for people with hemophilia.
Which is the Biggest Drug Class Segment in the Hemophilia Treatment Market?
“Sales of Vasopressin to Rise at a Considerable Pace in the Market”
According to Future Market Insights, the vasopressin segment leads the hemophilia treatment market and it is likely to hold a large portion of the market share by 2032. Growth of the segment is attributed to increasing usage of vasopressin for preventing bleeding of joints & muscles, nose, and mouth as well as improving the survival chances of critically ill patients.
Which is the Preferred Route of Administration?
“Injectable Remains Preferred Route of Administration”
As per FMI, the injectable segment will continue to dominate the global hemophilia treatment market, owing to the rising preference for administering hemophilia treatment drugs through injectable mode, on account of its user friendly and fast acting nature.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Competitive Landscape
The global hemophilia treatment market is highly dynamic in nature with leading hemophilia treatment companies vigorously investing in research and development for introducing novel therapies. Besides this, they have adopted growth strategies such as partnerships, mergers, acquisitions, new product launches and approvals, collaborations etc. to gain a competitive edge in the global hemophilia treatment market. For instance,
- In 2020, Novo Nordisk announced the launch of ESPEROCT®, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding in individuals with hemophilia A.
- In April 2020, the U.S. Food and Drug Administration approved Sevenfact for the treatment of adults suffering from hemophilia A and B.
- In 2022, Takeda Pharmaceutical Company Limited launched Adynovate, an extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A patients in India.
Hemophilia Treatment Market-Scope of The Report
FMI’s latest report on the hemophilia treatment market provides a detailed analysis of key growth shaping factors like drivers, restraints, and emerging opportunities. It examines current hemophilia treatment drugs industry trends and highlights their impact on the overall demand for hemophilia treatment.
The report analyzes various hemophilia treatment market segments and regional pockets with the aim of providing a deeper understanding of leading segments. It illustrates how escalation in novel drug development and approvals will increase hemophilia market share during the forthcoming years.
FMI also attempts to provide answers to queries like how will rise in hemophilia cases influence hemophilia treatment sales? Why is North America a pivotal hemophilia treatment market? And Which factors are pushing the demand for hemophilia treatments across Asia Pacific? Detailed information on this is compiled in the global hemophilia treatment market report, which is interspersed with relevant statistics and graphs.
The Hemophilia Treatment Market analysis includes:
- A 10-year realistic hemophilia treatment sales forecast slicing across several verticals
- Comprehensive information on demand forecasting and sales prospects across 25 countries
- Insights into latest hemophilia treatment market trends
- Data about leading segments and regional pockets along with their respective shares and growth forecast
- Market dynamics including drivers, restraints and emerging opportunities
- Top hemophilia drug companies and their growth strategies
- Information about the impact of expanding drug discovery services market on the overall demand for hemophilia treatments
- Recent developments in hemophilia treatment market
- The winning imperatives in hemophilia treatment market
|
Attribute |
Details |
|
Forecast Period |
2022-2032 |
|
Historic Data Available for |
2015-2021 |
|
Market Analysis |
USD Million for Value |
|
Report Coverage |
Market forecast, company share analysis, competition intelligence, DROT analysis, market dynamics and challenges, and strategic growth initiatives |
|
Key Segments Covered |
|
|
Key regions covered |
|
|
Therapy |
|
|
Key companies profiled |
Biotest AG, Pfizer, CSL Behring, Biogen, Kedrion, Ferring B.V, Genentech, Novo Nordisk, and Octapharma. |
|
Customization & pricing |
Available upon request |
Key Segments
By Disease:
- Hemophilia A
- Hemophilia B
By Patient:
- Paediatric
- Adult
By Treatment:
- Prophylaxis
- On Demand
By Therapy:
- Factor Replacement Therapy
- Non-factor Replacement Therapy
By Drug Class:
- Vasopressin
- Coagulation Factor
By Route of Administration:
- Injectable
- Nasal Spray
By Region:
- North America
- Latin America
- Asia Pacific
- Europe
- Middle East & Africa
Frequently Asked Questions
How much was the global hemophilia treatment market worth in 2021?
The global hemophilia treatment market was valued at US$ 11.1 Bn in 2021.
What is the growth outlook for the hemophilia treatment market?
As per FMI, the hemophilia treatment market is expected to grow at a steady CAGR of 4.8% during the projected period.
Which region dominates the global hemophilia treatment market?
North America will continue to lead the global hemophilia treatment market.
Who are the leading players in the hemophilia treatment market?
Biogen, CSL Behring Biotest AG, CSL Behring, Ferring B.V, Genentech, Kedrion, Novo Nordisk, Pfizer and Octapharma are some of the prominent players operating in the hemophilia treatment market.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. FMI Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Hemophilia TreatmentDemand 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Mn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Hemophilia Treatment By Country, US$ Mn 4.2. Hemophilia TreatmentMarket Opportunity Assessment (US$ Mn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Imp 4.5.1. Top Companies Historical Growth 4.5.2. Global Hemophilia Treatment Growth 4.5.3. Hemophilia TreatmentAdoption Rate, By Country 4.5.4. Investments in 3D Printing Technology 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Hemophilia TreatmentMarket Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Hemophilia TreatmentMarket Demand Analysis 2015-2021 and Forecast, 2022-2032 6.1. Historical Market Analysis, 2015-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Hemophilia TreatmentMarket Value Analysis 2015-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032,By Disease 8.1. Introduction / Key Findings 8.2. Historical Market Value (US$ Mn) and AnalysisBy Disease , 2015-2021 8.3. Current and Future Market Value (US$ Mn) and Analysis and ForecastBy Disease , 2022-2032 8.3.1. Hemophilia A 8.3.1.1. Severe 8.3.1.2. Moderate 8.3.1.3. Mild 8.3.2. Hemophilia B 8.3.2.1. Severe 8.3.2.2. Moderate 8.3.2.3. Mild 8.4. Market Attractiveness AnalysisBy Disease 9. Global Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Value (US$ Mn) and Analysis By Product , 2015-2021 9.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Product , 2022-2032 9.3.1. Recombinant Factor Concentrates 9.3.1.1. Factor VIII 9.3.1.2. Factor IX 9.3.2. Plasma-derived Factor Concentrates 9.3.2.1. Factor VIII 9.3.2.2. Factor IX 9.3.3. Extended Half-life Products 9.3.3.1. Factor VIII 9.3.3.2. Factor IX 9.3.4. Others 9.4. Market Attractiveness Analysis By Product 10. Global Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032, By Patient 10.1. Introduction / Key Findings 10.2. Historical Market Value (US$ Mn) and Analysis By Patient , 2015-2021 10.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Patient , 2022-2032 10.3.1. Pediatric 10.3.1.1. 0 to 4 10.3.1.2. 5 to 13 10.3.1.3. 14 to18 10.3.2. Adult 10.3.2.1. 19 to 44 10.3.2.2. 45+ 10.4. Market Attractiveness Analysis By Patient 11. Global Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032, By Treatment 11.1. Introduction / Key Findings 11.2. Historical Market Value (US$ Mn) and Analysis By Deployment Mode, 2015-2021 11.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Deployment Mode, 2022-2032 11.3.1. Prophylaxis 11.3.2. On Demand 11.4. Market Attractiveness Analysis By Deployment Mode 12. Global Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032, By Therapy 12.1. Introduction / Key Findings 12.2. Historical Market Value (US$ Mn) and Analysis By Therapy , 2015-2021 12.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Therapy , 2022-2032 12.3.1. Factor Replacement Therapy 12.3.2. Non-factor Replacement Therapy 12.4. Market Attractiveness Analysis By Therapy 13. Global Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032,By Drug Class 13.1. Introduction / Key Findings 13.2. Historical Market Value (US$ Mn) and Analysis By Drug Class , 2015-2021 13.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Drug Class , 2022-2032 13.3.1. Vasopressin 13.3.2. Coagulation Factors 13.4. Market Attractiveness Analysis By Drug Class 14. Global Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032, By Route of Administration 14.1. Introduction / Key Findings 14.2. Historical Market Value (US$ Mn) and Analysis By Route of Administration , 2015-2021 14.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Route of Administration , 2022-2032 14.3.1. Injectable 14.3.2. Nasal Spray 14.4. Market Attractiveness Analysis By Route of Administration 15. Global Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032, By Region 15.1. Introduction 15.2. Historical Market Value (US$ Mn) and Analysis By Region, 2015-2021 15.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032 15.3.1. North America 15.3.2. Latin America 15.3.3. Europe 15.3.4. Asia Pacefic 15.3.5. Middle East and Africa (MEA) 15.4. Market Attractiveness Analysis By Region 16. North America Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021 16.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 16.4.1. By Country 16.4.1.1. U.S. 16.4.1.2. Canada 16.4.2. By Patient 16.4.3. By Disease 16.4.4. By Product 16.4.5. By Treatment 16.4.6. By Therapy 16.4.7. By Route of Administration 16.4.8. By Drug Class 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Patient 16.5.3. By Disease 16.5.4. By Product 16.5.5. By Treatment 16.5.6. By Therapy 16.5.7. By Route of Administration 16.5.8. By Drug Class 17. Latin America Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021 17.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 17.4.1. By Country 17.4.1.1. Brazil 17.4.1.2. Mexico 17.4.1.3. Rest of Latin America 17.4.2. By Patient 17.4.3. By Disease 17.4.4. By Product 17.4.5. By Treatment 17.4.6. By Therapy 17.4.7. By Route of Administration 17.4.8. By Drug Class 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Patient 17.5.3. By Disease 17.5.4. By Product 17.5.5. By Treatment 17.5.6. By Therapy 17.5.7. By Route of Administration 17.5.8. By Drug Class 18. Europe Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032 18.1. Introduction 18.2. Pricing Analysis 18.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021 18.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 18.4.1. By Country 18.4.1.1. Germany 18.4.1.2. France 18.4.1.3. U.K. 18.4.1.4. Italy 18.4.1.5. Russia 18.4.1.6. Rest of Europe 18.4.2. By Patient 18.4.3. By Disease 18.4.4. By Product 18.4.5. By Treatment 18.4.6. By Therapy 18.4.7. By Route of Administration 18.4.8. By Drug Class 18.5. Market Attractiveness Analysis 18.5.1. By Country 18.5.2. By Patient 18.5.3. By Disease 18.5.4. By Product 18.5.5. By Treatment 18.5.6. By Therapy 18.5.7. By Route of Administration 18.5.8. By Drug Class 19. Asia Pacific Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032 19.1. Introduction 19.2. Pricing Analysis 19.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021 19.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 19.4.1. By Country 19.4.1.1. China 19.4.1.2. Japan 19.4.1.3. South Korea 19.4.1.4. Rest of Asia Pacific 19.4.2. By Patient 19.4.3. By Disease 19.4.4. By Product 19.4.5. By Treatment 19.4.6. By Therapy 19.4.7. By Route of Administration 19.4.8. By Drug Class 19.5. Market Attractiveness Analysis 19.5.1. By Country 19.5.2. By Patient 19.5.3. By Disease 19.5.4. By Product 19.5.5. By Treatment 19.5.6. By Therapy 19.5.7. By Route of Administration 19.5.8. By Drug Class 20. Middle East and Africa Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032 20.1. Introduction 20.2. Pricing Analysis 20.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021 20.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 20.4.1. By Country 20.4.1.1. GCC Countries 20.4.1.2. South Africa 20.4.1.3. Turkey 20.4.1.4. Rest of Middle East and Africa 20.4.2. By Patient 20.4.3. By Disease 20.4.4. By Product 20.4.5. By Treatment 20.4.6. By Therapy 20.4.7. By Route of Administration 20.4.8. By Drug Class 20.5. Market Attractiveness Analysis 20.5.1. By Country 20.5.2. By Patient 20.5.3. By Disease 20.5.4. By Product 20.5.5. By Treatment 20.5.6. By Therapy 20.5.7. By Route of Administration 20.5.8. By Drug Class 21. Key Countries Hemophilia TreatmentMarket Analysis 2015-2021 and Forecast 2022-2032 21.1. Introduction 21.1.1. Market Value Proportion Analysis, By Key Countries 21.1.2. Global Vs. Country Growth Comparison 21.2. US Hemophilia TreatmentMarket Analysis 21.2.1. Value Proportion Analysis by Market Taxonomy 21.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.2.2.1. By Patient 21.2.2.2. By Disease 21.2.2.3. By Product 21.2.2.4. By Treatment 21.2.2.5. By Therapy 21.2.2.6. By Route of Administration 21.2.2.7. By Drug Class 21.3. Canada Hemophilia TreatmentMarket Analysis 21.3.1. Value Proportion Analysis by Market Taxonomy 21.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.3.2.1. By Patient 21.3.2.2. By Disease 21.3.2.3. By Product 21.3.2.4. By Treatment 21.3.2.5. By Therapy 21.3.2.6. By Route of Administration 21.3.2.7. By End-User 21.4. Mexico Hemophilia TreatmentMarket Analysis 21.4.1. Value Proportion Analysis by Market Taxonomy 21.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.4.2.1. By Patient 21.4.2.2. By Disease 21.4.2.3. By Product 21.4.2.4. By Treatment 21.4.2.5. By Therapy 21.4.2.6. By Route of Administration 21.4.2.7. By End-User 21.5. Brazil Hemophilia TreatmentMarket Analysis 21.5.1. Value Proportion Analysis by Market Taxonomy 21.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.5.2.1. By Patient 21.5.2.2. By Disease 21.5.2.3. By Product 21.5.2.4. By Treatment 21.5.2.5. By Therapy 21.5.2.6. By Route of Administration 21.5.2.7. By End-User 21.6. Germany Hemophilia TreatmentMarket Analysis 21.6.1. Value Proportion Analysis by Market Taxonomy 21.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.6.2.1. By Patient 21.6.2.2. By Disease 21.6.2.3. By Product 21.6.2.4. By Treatment 21.6.2.5. By Therapy 21.6.2.6. By Route of Administration 21.6.2.7. By End-User 21.7. France Hemophilia TreatmentMarket Analysis 21.7.1. Value Proportion Analysis by Market Taxonomy 21.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.7.2.1. By Patient 21.7.2.2. By Disease 21.7.2.3. By Product 21.7.2.4. By Treatment 21.7.2.5. By Therapy 21.7.2.6. By Route of Administration 21.7.2.7. By End-User 21.8. Italy Hemophilia TreatmentMarket Analysis 21.8.1. Value Proportion Analysis by Market Taxonomy 21.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.8.2.1. By Patient 21.8.2.2. By Disease 21.8.2.3. By Product 21.8.2.4. By Treatment 21.8.2.5. By Therapy 21.8.2.6. By Route of Administration 21.8.2.7. By End-User 21.9. Russia Hemophilia TreatmentMarket Analysis 21.9.1. Value Proportion Analysis by Market Taxonomy 21.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.9.2.1. By Patient 21.9.2.2. By Disease 21.9.2.3. By Product 21.9.2.4. By Treatment 21.9.2.5. By Therapy 21.9.2.6. By Route of Administration 21.9.2.7. By End-User 21.10. UK Hemophilia TreatmentMarket Analysis 21.10.1. Value Proportion Analysis by Market Taxonomy 21.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.10.2.1. By Patient 21.10.2.2. By Disease 21.10.2.3. By Product 21.10.2.4. By Treatment 21.10.2.5. By Therapy 21.10.2.6. By Route of Administration 21.10.2.7. By End-User 21.11. China Hemophilia TreatmentMarket Analysis 21.11.1. Value Proportion Analysis by Market Taxonomy 21.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.11.2.1. By Patient 21.11.2.2. By Disease 21.11.2.3. By Product 21.11.2.4. By Treatment 21.11.2.5. By Therapy 21.11.2.6. By Route of Administration 21.11.2.7. By End-User 21.12. Japan Hemophilia TreatmentMarket Analysis 21.12.1. Value Proportion Analysis by Market Taxonomy 21.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.12.2.1. By Patient 21.12.2.2. By Disease 21.12.2.3. By Product 21.12.2.4. By Treatment 21.12.2.5. By Therapy 21.12.2.6. By Route of Administration 21.12.2.7. By End-User 21.13. South Korea Hemophilia TreatmentMarket Analysis 21.13.1. Value Proportion Analysis by Market Taxonomy 21.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.13.2.1. By Patient 21.13.2.2. By Disease 21.13.2.3. By Product 21.13.2.4. By Treatment 21.13.2.5. By Therapy 21.13.2.6. By Route of Administration 21.13.2.7. By End-User 21.14. GCC Countries Hemophilia TreatmentMarket Analysis 21.14.1. Value Proportion Analysis by Market Taxonomy 21.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.14.2.1. By Patient 21.14.2.2. By Disease 21.14.2.3. By Product 21.14.2.4. By Treatment 21.14.2.5. By Therapy 21.14.2.6. By Route of Administration 21.14.2.7. By End-User 21.15. South Africa Hemophilia TreatmentMarket Analysis 21.15.1. Value Proportion Analysis by Market Taxonomy 21.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.15.2.1. By Patient 21.15.2.2. By Disease 21.15.2.3. By Product 21.15.2.4. By Treatment 21.15.2.5. By Therapy 21.15.2.6. By Route of Administration 21.15.2.7. By End-User 21.16. Turkey Hemophilia TreatmentMarket Analysis 21.16.1. Value Proportion Analysis by Market Taxonomy 21.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 21.16.2.1. By Patient 21.16.2.2. By Disease 21.16.2.3. By Product 21.16.2.4. By Treatment 21.16.2.5. By Therapy 21.16.2.6. By Route of Administration 21.16.2.7. By End-User 21.16.3. Competition Landscape and Player Concentration in the Country 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Concentration 22.3. Market Share Analysis of Top Players 22.4. Market Presence Analysis 22.4.1. By Regional footprint of Players 22.4.2. Product footprint by Players 23. Competition Analysis 23.1. Competition Dashboard 23.2. Competition Benchmarking 23.3. Competition Deep Dive 23.3.1. Bayer Healthcare 23.3.1.1. Overview 23.3.1.2. Product Portfolio 23.3.1.3. Sales Footprint 23.3.1.4. Strategy Overview 23.3.2. Biogen 23.3.2.1. Overview 23.3.2.2. Product Portfolio 23.3.2.3. Sales Footprint 23.3.2.4. Strategy Overview 23.3.3. Biotest AG 23.3.3.1. Overview 23.3.3.2. Product Portfolio 23.3.3.3. Sales Footprint 23.3.3.4. Strategy Overview 23.3.4. CSL Behring 23.3.4.1. Overview 23.3.4.2. Product Portfolio 23.3.4.3. Sales Footprint 23.3.4.4. Strategy Overview 23.3.5. Ferring B.V 23.3.5.1. Overview 23.3.5.2. Product Portfolio 23.3.5.3. Sales Footprint 23.3.5.4. Strategy Overview 23.3.6. Genentech 23.3.6.1. Overview 23.3.6.2. Product Portfolio 23.3.6.3. Sales Footprint 23.3.6.4. Strategy Overview 23.3.7. Kedrion 23.3.7.1. Overview 23.3.7.2. Product Portfolio 23.3.7.3. Sales Footprint 23.3.7.4. Strategy Overview 23.3.8. Novo Nordisk 23.3.8.1. Overview 23.3.8.2. Product Portfolio 23.3.8.3. Sales Footprint 23.3.8.4. Strategy Overview 23.3.9. Octapharma 23.3.9.1. Overview 23.3.9.2. Product Portfolio 23.3.9.3. Sales Footprint 23.3.9.4. Strategy Overview 23.3.10. Pfizer 23.3.10.1. Overview 23.3.10.2. Product Portfolio 23.3.10.3. Sales Footprint 23.3.10.4. Strategy Overview 24. Assumptions and Acronyms Used 25. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Hemophilia Treatment Market Value (US$ Mn), By Patient , 2015 – 2021 Table 2: Global Hemophilia Treatment Market Value (US$ Mn), By Patient , 2022 – 2032 Table 3: Global Hemophilia Treatment Market Value (US$ Mn),By Disease , 2015 – 2021 Table 4: Global Hemophilia Treatment Market Value (US$ Mn),By Disease , 2022 – 2032 Table 5: Global Hemophilia Treatment Market Value (US$ Mn), By Product , 2015 – 2021 Table 6: Global Hemophilia Treatment Market Value (US$ Mn), By Product , 2022 – 2032 Table 7: Global Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2015 – 2021 Table 8: Global Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2022 – 2032 Table 9: Global Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2015 – 2021 Table 10: Global Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2022 – 2032 Table 11: Global Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2015 – 2021 Table 12: Global Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2022 – 2032 Table 13: Global Hemophilia Treatment Market Value (US$ Mn), By End-User, 2015 – 2021 Table 14: Global Hemophilia Treatment Market Value (US$ Mn), By End-User, 2022 – 2032 Table 15: Global Hemophilia Treatment Market, By Region, 2015 – 2021 Table 16: Global Hemophilia Treatment Market, By Region, 2022 – 2032 Table 17: North America Hemophilia Treatment Market Value (US$ Mn), By Patient , 2015 – 2021 Table 18: North America Hemophilia Treatment Market Value (US$ Mn), By Patient , 2022 – 2032 Table 19: North America Hemophilia Treatment Market Value (US$ Mn),By Disease , 2015 – 2021 Table 20: North America Hemophilia Treatment Market Value (US$ Mn),By Disease , 2022 – 2032 Table 21: North America Hemophilia Treatment Market Value (US$ Mn), By Product , 2015 – 2021 Table 22: North America Hemophilia Treatment Market Value (US$ Mn), By Product , 2022 – 2032 Table 23: North America Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2015 – 2021 Table 24: North America Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2022 – 2032 Table 25: North America Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2015 – 2021 Table 26: North America Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2022 – 2032 Table 27: North America Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2015 – 2021 Table 28: North America Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2022 – 2032 Table 29: North America Hemophilia Treatment Market Value (US$ Mn), By End-User, 2015 – 2021 Table 30: North America Hemophilia Treatment Market Value (US$ Mn), By End-User, 2022 – 2032 Table 31: North America Hemophilia Treatment Market, By Country, 2015 – 2021 Table 32: North America Hemophilia Treatment Market, By Country, 2022 – 2032 Table 33: Latin America Hemophilia Treatment Market Value (US$ Mn), By Patient , 2015 – 2021 Table 34: Latin America Hemophilia Treatment Market Value (US$ Mn), By Patient , 2022 – 2032 Table 35: Latin America Hemophilia Treatment Market Value (US$ Mn),By Disease , 2015 – 2021 Table 36: Latin America Hemophilia Treatment Market Value (US$ Mn),By Disease , 2022 – 2032 Table 37: Latin America Hemophilia Treatment Market Value (US$ Mn), By Product , 2015 – 2021 Table 38: Latin America Hemophilia Treatment Market Value (US$ Mn), By Product , 2022 – 2032 Table 39: Latin America Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2015 – 2021 Table 40: Latin America Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2022 – 2032 Table 41: Latin America Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2015 – 2021 Table 42: Latin America Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2022 – 2032 Table 43: Latin America Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2015 – 2021 Table 44: Latin America Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2022 – 2032 Table 45: Latin America Hemophilia Treatment Market Value (US$ Mn), By End-User2015 – 2021 Table 46: Latin America Hemophilia Treatment Market Value (US$ Mn), By End-User, 2022 – 2032 Table 47: Latin America Hemophilia Treatment Market, By Country, 2015 – 2021 Table 48: Latin America Hemophilia Treatment Market, By Country, 2022 – 2032 Table 49: Europe Hemophilia Treatment Market Value (US$ Mn), By Patient , 2015 – 2021 Table 50: Europe Hemophilia Treatment Market Value (US$ Mn), By Patient , 2022 – 2032 Table 51: Europe Hemophilia Treatment Market Value (US$ Mn),By Disease , 2015 – 2021 Table 52: Europe Hemophilia Treatment Market Value (US$ Mn),By Disease , 2022 – 2032 Table 53: Europe Hemophilia Treatment Market Value (US$ Mn), By Product , 2015 – 2021 Table 54: Europe Hemophilia Treatment Market Value (US$ Mn), By Product , 2022 – 2032 Table 55: Europe Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2015 – 2021 Table 56: Europe Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2022 – 2032 Table 57: Europe Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2015 – 2021 Table 58: Europe Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2022 – 2032 Table 59: Europe Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2015 – 2021 Table 60: Europe Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2022 – 2032 Table 61: Europe Hemophilia Treatment Market Value (US$ Mn), By End-User, 2015 – 2021 Table 62: Europe Hemophilia Treatment Market Value (US$ Mn), By End-User, 2022 – 2032 Table 63: Europe Hemophilia Treatment Market, By Country, 2015 – 2021 Table 64: Europe Hemophilia Treatment Market, By Country, 2022 – 2032 Table 65: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Patient , 2015 – 2021 Table 66: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Patient , 2022 – 2032 Table 67: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn),By Disease , 2015 – 2021 Table 68: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn),By Disease , 2022 – 2032 Table 69: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Product , 2015 – 2021 Table 70: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Product , 2022 – 2032 Table 71: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2015 – 2021 Table 72: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2022 – 2032 Table 73: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2015 – 2021 Table 74: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2022 – 2032 Table 75: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2015 – 2021 Table 76: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2022 – 2032 Table 77: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By End-User, 2015 – 2021 Table 78: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn), By End-User, 2022 – 2032 Table 79: Asia Pacefic Hemophilia Treatment Market, By Country, 2015 – 2021 Table 80: Asia Pacefic Hemophilia Treatment Market, By Country, 2022 – 2032 Table 81: MEA Hemophilia Treatment Market Value (US$ Mn), By Patient , 2015 – 2021 Table 82: MEA Hemophilia Treatment Market Value (US$ Mn), By Patient , 2022 – 2032 Table 83: MEA Hemophilia Treatment Market Value (US$ Mn),By Disease , 2015 – 2021 Table 84: MEA Hemophilia Treatment Market Value (US$ Mn),By Disease , 2022 – 2032 Table 85: MEA Hemophilia Treatment Market Value (US$ Mn), By Product , 2015 – 2021 Table 86: MEA Hemophilia Treatment Market Value (US$ Mn), By Product , 2022 – 2032 Table 87: MEA Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2015 – 2021 Table 88: MEA Hemophilia Treatment Market Value (US$ Mn), By Therapy , 2022 – 2032 Table 89: MEA Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2015 – 2021 Table 90: MEA Hemophilia Treatment Market Value (US$ Mn), By Route of Administration , 2022 – 2032 Table 91: MEA Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2015 – 2021 Table 92: MEA Hemophilia Treatment Market Value (US$ Mn), By Deployment Mode, 2022 – 2032 Table 93: MEA Hemophilia Treatment Market Value (US$ Mn), By End-User, 2015 – 2021 Table 94: MEA Hemophilia Treatment Market Value (US$ Mn), By Drug Class 2022 – 2032 Table 95: MEA Hemophilia Treatment Market, By Country, 2015 – 2021 Table 96: MEA Hemophilia Treatment Market, By Country, 2022 – 2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Hemophilia Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032 Figure 2: Global Hemophilia Treatment Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn Figure 3: Global Hemophilia Treatment Market Share, By Patient , 2022 & 2032 Figure 4: Global Hemophilia Treatment Market Y-o-Y Growth Projections, By Patient – 2022-2032 Figure 5: Global Hemophilia Treatment Market Attractiveness Index, By Patient – 2022-2032 Figure 6: Global Hemophilia Treatment Market Share,By Disease , 2022 & 2032 Figure 7: Global Hemophilia Treatment Market Y-o-Y Growth Projections,By Disease – 2022-2032 Figure 8: Global Hemophilia Treatment Market Attractiveness Index,By Disease – 2022-2032 Figure 9: Global Hemophilia Treatment Market Share, By Therapy , 2022 & 2032 Figure 10: Global Hemophilia Treatment Market Y-o-Y Growth Projections, By Therapy – 2022-2032 Figure 11: Global Hemophilia Treatment Market Attractiveness Index, By Therapy – 2022-2032 Figure 12: Global Hemophilia Treatment Market Share, By Route of Administration , 2022 & 2032 Figure 13: Global Hemophilia Treatment Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032 Figure 14: Global Hemophilia Treatment Market Attractiveness Index, By Route of Administration – 2022-2032 Figure 15: Global Hemophilia Treatment Market Share, By Product , 2022 & 2032 Figure 16: Global Hemophilia Treatment Market Y-o-Y Growth Projections, By Product – 2022-2032 Figure 17: Global Hemophilia Treatment Market Attractiveness Index, By Product – 2022-2032 Figure 18: Global Hemophilia Treatment Market Share, By Deployment Mode, 2022 & 2032 Figure 19: Global Hemophilia Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032 Figure 20: Global Hemophilia Treatment Market Attractiveness Index, By Treatment – 2022-2032 Figure 21: Global Hemophilia Treatment Market Share, By End-User, 2022 & 2032 Figure 22: Global Hemophilia Treatment Market Y-o-Y Growth Projections, By Drug Class – 2022-2032 Figure 23: Global Hemophilia Treatment Market Y-o-Y Growth Projections, By End-User– 2022-2032 Figure 24: Global Hemophilia Treatment Market Share, By Region, 2022 & 2032 Figure 25: Global Hemophilia Treatment Market Y-o-Y Growth Projections, By Region – 2022-2032 Figure 26: Global Hemophilia Treatment Market Attractiveness Index, By Region – 2022-2032 Figure 27: North America Hemophilia Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032 Figure 28: North America Hemophilia Treatment Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn Figure 29: North America Hemophilia Treatment Market Share, By Patient , 2022 & 2032 Figure 30: North America Hemophilia Treatment Market Y-o-Y Growth Projections, By Patient – 2022-2032 Figure 31: North America Hemophilia Treatment Market Attractiveness Index, By Patient – 2022-2032 Figure 32: North America Hemophilia Treatment Market Share,By Disease , 2022 & 2032 Figure 33: North America Hemophilia Treatment Market Y-o-Y Growth Projections,By Disease – 2022-2032 Figure 34: North America Hemophilia Treatment Market Attractiveness Index,By Disease – 2022-2032 Figure 35: North America Hemophilia Treatment Market Share, By Therapy , 2022 & 2032 Figure 36: North America Hemophilia Treatment Market Y-o-Y Growth Projections, By Therapy – 2022-2032 Figure 37: North America Hemophilia Treatment Market Attractiveness Index, By Therapy – 2022-2032 Figure 38: North America Hemophilia Treatment Market Share, By Route of Administration , 2022 & 2032 Figure 39: North America Hemophilia Treatment Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032 Figure 40: North America Hemophilia Treatment Market Attractiveness Index, By Route of Administration – 2022-2032 Figure 41: North America Hemophilia Treatment Market Share, By Product , 2022 & 2032 Figure 42: North America Hemophilia Treatment Market Y-o-Y Growth Projections, By Product – 2022-2032 Figure 43: North America Hemophilia Treatment Market Attractiveness Index, By Product – 2022-2032 Figure 44: North America Hemophilia Treatment Market Share, By Deployment Mode, 2022 & 2032 Figure 45: North America Hemophilia Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032 Figure 46: North America Hemophilia Treatment Market Attractiveness Index, By Treatment – 2022-2032 Figure 47: North America Hemophilia Treatment Market Share, By End-User, 2022 & 2032 Figure 48: North America Hemophilia Treatment Market Y-o-Y Growth Projections, By Drug Class – 2022-2032 Figure 49: North America Hemophilia Treatment Market Attractiveness Index, By Drug Class – 2022-2032 Figure 50: North America Hemophilia Treatment Market Share, By Country, 2022 & 2032 Figure 51: North America Hemophilia Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032 Figure 52: North America Hemophilia Treatment Market Attractiveness Index, By Country – 2022-2032 Figure 53: Latin America Hemophilia Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032 Figure 54: Latin America Hemophilia Treatment Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn Figure 55: Latin America Hemophilia Treatment Market Share, By Patient , 2022 & 2032 Figure 56: Latin America Hemophilia Treatment Market Y-o-Y Growth Projections, By Patient – 2022-2032 Figure 57: Latin America Hemophilia Treatment Market Attractiveness Index, By Patient – 2022-2032 Figure 58: Latin America Hemophilia Treatment Market Share,By Disease , 2022 & 2032 Figure 59: Latin America Hemophilia Treatment Market Y-o-Y Growth Projections,By Disease – 2022-2032 Figure 60: Latin America Hemophilia Treatment Market Attractiveness Index,By Disease – 2022-2032 Figure 61: Latin America Hemophilia Treatment Market Share, By Therapy , 2022 & 2032 Figure 62: Latin America Hemophilia Treatment Market Y-o-Y Growth Projections, By Therapy – 2022-2032 Figure 63: Latin America Hemophilia Treatment Market Attractiveness Index, By Therapy – 2022-2032 Figure 64: Latin America Hemophilia Treatment Market Share, By Route of Administration , 2022 & 2032 Figure 65: Latin America Hemophilia Treatment Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032 Figure 66: Latin America Hemophilia Treatment Market Attractiveness Index, By Route of Administration – 2022-2032 Figure 67: Latin America Hemophilia Treatment Market Share, By Product , 2022 & 2032 Figure 68: Latin America Hemophilia Treatment Market Y-o-Y Growth Projections, By Product – 2022-2032 Figure 69: Latin America Hemophilia Treatment Market Attractiveness Index, By Product – 2022-2032 Figure 70: Latin America Hemophilia Treatment Market Share, By Deployment Mode, 2022 & 2032 Figure 71: Latin America Hemophilia Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032 Figure 72: Latin America Hemophilia Treatment Market Attractiveness Index, By Treatment – 2022-2032 Figure 73: Latin America Hemophilia Treatment Market Share, By End-User, 2022 & 2032 Figure 74: Latin America Hemophilia Treatment Market Y-o-Y Growth Projections, By Drug Class – 2022-2032 Figure 75: Latin America Hemophilia Treatment Market Attractiveness Index, By Drug Class – 2022-2032 Figure 76: Latin America Hemophilia Treatment Market Share, By Country, 2022 & 2032 Figure 77: Latin America Hemophilia Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032 Figure 78: Latin America Hemophilia Treatment Market Attractiveness Index, By Country – 2022-2032 Figure 79: Europe Hemophilia Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032 Figure 80: Europe Hemophilia Treatment Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn Figure 81: Europe Hemophilia Treatment Market Share, By Patient , 2022 & 2032 Figure 82: Europe Hemophilia Treatment Market Y-o-Y Growth Projections, By Patient – 2022-2032 Figure 83: Europe Hemophilia Treatment Market Attractiveness Index, By Patient – 2022-2032 Figure 84: Europe Hemophilia Treatment Market Share,By Disease , 2022 & 2032 Figure 85: Europe Hemophilia Treatment Market Y-o-Y Growth Projections,By Disease – 2022-2032 Figure 86: Europe Hemophilia Treatment Market Attractiveness Index,By Disease – 2022-2032 Figure 87: Europe Hemophilia Treatment Market Share, By Therapy , 2022 & 2032 Figure 88: Europe Hemophilia Treatment Market Y-o-Y Growth Projections, By Therapy – 2022-2032 Figure 89: Europe Hemophilia Treatment Market Attractiveness Index, By Therapy – 2022-2032 Figure 90: Europe Hemophilia Treatment Market Share, By Route of Administration , 2022 & 2032 Figure 91: Europe Hemophilia Treatment Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032 Figure 92: Europe Hemophilia Treatment Market Attractiveness Index, By Route of Administration – 2022-2032 Figure 93: Europe Hemophilia Treatment Market Share, By Product , 2022 & 2032 Figure 94: Europe Hemophilia Treatment Market Y-o-Y Growth Projections, By Product – 2022-2032 Figure 95: Europe Hemophilia Treatment Market Attractiveness Index, By Product – 2022-2032 Figure 96: Europe Hemophilia Treatment Market Share, By Deployment Mode, 2022 & 2032 Figure 97: Europe Hemophilia Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032 Figure 98: Europe Hemophilia Treatment Market Attractiveness Index, By Treatment – 2022-2032 Figure 99: Europe Hemophilia Treatment Market Share, By End-User, 2022 & 2032 Figure 100: Europe Hemophilia Treatment Market Y-o-Y Growth Projections, By Drug Class – 2022-2032 Figure 101: Europe Hemophilia Treatment Market Attractiveness Index, By Drug Class – 2022-2032 Figure 102: Europe Hemophilia Treatment Market Share, By Country, 2022 & 2032 Figure 103: Europe Hemophilia Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032 Figure 104: Europe Hemophilia Treatment Market Attractiveness Index, By Country – 2022-2032 Figure 105: Asia Pacefic Hemophilia Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032 Figure 106: Asia Pacefic Hemophilia Treatment Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn Figure 107: Asia Pacefic Hemophilia Treatment Market Share, By Patient , 2022 & 2032 Figure 108: Asia Pacefic Hemophilia Treatment Market Y-o-Y Growth Projections, By Patient – 2022-2032 Figure 109: Asia Pacefic Hemophilia Treatment Market Attractiveness Index, By Patient – 2022-2032 Figure 110: Asia Pacefic Hemophilia Treatment Market Share,By Disease , 2022 & 2032 Figure 111: Asia Pacefic Hemophilia Treatment Market Y-o-Y Growth Projections,By Disease – 2022-2032 Figure 112: Asia Pacefic Hemophilia Treatment Market Attractiveness Index,By Disease – 2022-2032 Figure 113: Asia Pacefic Hemophilia Treatment Market Share, By Therapy , 2022 & 2032 Figure 114: Asia Pacefic Hemophilia Treatment Market Y-o-Y Growth Projections, By Therapy – 2022-2032 Figure 115: Asia Pacefic Hemophilia Treatment Market Attractiveness Index, By Therapy – 2022-2032 Figure 116: Asia Pacefic Hemophilia Treatment Market Share, By Route of Administration , 2022 & 2032 Figure 117: Asia Pacefic Hemophilia Treatment Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032 Figure 118: Asia Pacefic Hemophilia Treatment Market Attractiveness Index, By Route of Administration – 2022-2032 Figure 119: Asia Pacefic Hemophilia Treatment Market Share, By Product , 2022 & 2032 Figure 120: Asia Pacefic Hemophilia Treatment Market Y-o-Y Growth Projections, By Product – 2022-2032 Figure 121: Asia Pacefic Hemophilia Treatment Market Attractiveness Index, By Product – 2022-2032 Figure 122: Asia Pacefic Hemophilia Treatment Market Share, By Deployment Mode, 2022 & 2032 Figure 123: Asia Pacefic Hemophilia Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032 Figure 124: Asia Pacefic Hemophilia Treatment Market Attractiveness Index, By Treatment – 2022-2032 Figure 125: Asia Pacefic Hemophilia Treatment Market Share, By End-User, 2022 & 2032 Figure 126: Asia Pacefic Hemophilia Treatment Market Y-o-Y Growth Projections, By Drug Class – 2022-2032 Figure 127: Asia Pacefic Hemophilia Treatment Market Attractiveness Index, By Drug Class – 2022-2032 Figure 128: Asia Pacefic Hemophilia Treatment Market Share, By Country, 2022 & 2032 Figure 129: Asia Pacefic Hemophilia Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032 Figure 130: Asia Pacefic Hemophilia Treatment Market Attractiveness Index, By Country – 2022-2032 Figure 131: MEA Hemophilia Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032 Figure 132: MEA Hemophilia Treatment Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn Figure 133: MEA Hemophilia Treatment Market Share, By Patient , 2022 & 2032 Figure 134: MEA Hemophilia Treatment Market Y-o-Y Growth Projections, By Patient – 2022-2032 Figure 135: MEA Hemophilia Treatment Market Attractiveness Index, By Patient – 2022-2032 Figure 136: MEA Hemophilia Treatment Market Share,By Disease , 2022 & 2032 Figure 137: MEA Hemophilia Treatment Market Y-o-Y Growth Projections,By Disease – 2022-2032 Figure 138: MEA Hemophilia Treatment Market Attractiveness Index,By Disease – 2022-2032 Figure 139: MEA Hemophilia Treatment Market Share, By Therapy , 2022 & 2032 Figure 140: MEA Hemophilia Treatment Market Y-o-Y Growth Projections, By Therapy – 2022-2032 Figure 141: MEA Hemophilia Treatment Market Attractiveness Index, By Therapy – 2022-2032 Figure 142: MEA Hemophilia Treatment Market Share, By Route of Administration , 2022 & 2032 Figure 143: MEA Hemophilia Treatment Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032 Figure 144: MEA Hemophilia Treatment Market Attractiveness Index, By Route of Administration – 2022-2032 Figure 145: MEA Hemophilia Treatment Market Share, By Product , 2022 & 2032 Figure 146: MEA Hemophilia Treatment Market Y-o-Y Growth Projections, By Product – 2022-2032 Figure 147: MEA Hemophilia Treatment Market Attractiveness Index, By Product – 2022-2032 Figure 148: MEA Hemophilia Treatment Market Share, By Deployment Mode, 2022 & 2032 Figure 149: MEA Hemophilia Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032 Figure 150: MEA Hemophilia Treatment Market Attractiveness Index, By Treatment – 2022-2032 Figure 151: MEA Hemophilia Treatment Market Share, By Drug Class 2022 & 2032 Figure 152: MEA Hemophilia Treatment Market Y-o-Y Growth Projections, By End-User– 2022-2032 Figure 153: MEA Hemophilia Treatment Market Attractiveness Index, By End-User– 2022-2032 Figure 154: MEA Hemophilia Treatment Market Share, By Country, 2022 & 2032 Figure 155: MEA Hemophilia Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032 Figure 156: MEA Hemophilia Treatment Market Attractiveness Index, By Country – 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
